The Women’s Interagency HIV Study (WIHS) is Now closed for referrals and recruitment of new participants (Closed Enrollment 4/30/2015).

Thanks you so much for being a part of the UAB-UMMC WIHS family.

    The University of Alabama at Birmingham (UAB) Women’s Interagency HIV Study better known as WIHS as well as our WIHS sister site at the University of Mississippi Medical Center (UMMC) have been going strong for three years now.

Our sincerest thanks to you all for so generously given up your time and self for these past three years. 
Through your efforts and time WIHS has generated over 600 publications and we are coming closer and closer to understanding the challenges that women face.
All of this is because of you. Thank you again for your efforts and your dedication. Please keep it coming!!!!!!!!!

We are happy to report that recruiting has closed at both the UAB and UMMC sites. We have a total of 115 women in our UAB cohort and 115 at our UMMC site.
We have been maintaining at least a 94% retention rate for our UAB site and 97% at our UMMC site.

Thanks to all of you that come faithfully to your WIHS appointments.
Remember each visit will include an interview, a short physical exam, a gyn exam with pap smear, and laboratory specimen collection.
To read more about the important studies and findings conducted by the WIHS cohort, review this list of recent studies.



Saag  hugThis study is currently closed to enrollment. Our site has enrolled 115 women in Alabama and 115 women in Mississippi who are culturally and ethnically diversity women that have HIV or at risk for HIV  This study is an observational study that does not provide medication or any other intervention treatment to our participants. If you choose to enroll in this study, you will be asked to provide data through
  1. Comprehensive Interviews
  2. Physical and gynecological medical examinations
  3. And collection of specimens that include blood, urine, hair, and cervical fluids.
Whether you are HIV positive or negative, the data you will provide will help increase scientific knowledge of HIV and its effect on the women's body. As an HIV negative participant, you data will be used to compare with the scientific finds gained from our HIV positive participants. Also you involvement in this study will provide you will knowledge of how HIV affects your own body through acquiring knowledge of you internal, gynecological and physical health. That's why every WIHS participant is so important!

If you have questions or would like to contact a WIHS staff person, please contact Zenoria Causey at UAB, 205-975-9128 and Venetra McKinney at UMMC at 601-815-51878

Eligibility Requirements

General Requirements

  • Women must be between ages 25-60 for both HIV-positive and HIV-negative recruits.
  • Willing to come every 6 months for clinic visit
  • Willing to have blood drawn, pelvic exam and answer study question

HIV negative (-)

The enrollment criteria that must be met by HIV-negative women are at least one of which must have been met in the five years prior to enrollment, are as follows:
  • Reported injection drug use, or use of crack, cocaine, heroin, or methamphetamine
  • Diagnosis by a health care provider with an STD
  • Reported having unprotected sex with three or more men
  • Reported having sex for drugs, money, or shelter
  • Reported having sex with six or more men
  • Reported having sex with known HIV-positive man
  • Partner reported injection drug use, or use of crack, cocaine, heroin, or methamphetamine
  • Partner diagnosed by a health care provider with an STD
  • Partner reported having unprotected sex with three or more women or men
  • Partner reported having sex for drugs, money, or shelter
  • Partner reported having sex with six or more women or men
  • Partner reported having sex with known HIV-positive woman or man

HIV positive (+)

  • HAART users must have started their first HAART regimen subsequent to December 31, 2004, unless the HAART use was during pregnancy or for PEP/PrEP only.
  • Women must not have ever used ddI (Videx, didanosine), ddC (Hivid, zalcitabine) or d4T (Zerit, stavudine) unless use was only during pregnancy or for PEP/PrEP.
  • Women may not be on non-HAART ART at time of enrollment and must not have used ART before starting HAART, unless use was only during pregnancy or for PEP/PrEP.
  • Women must be biologically female at birth.

WIHS National Community Advisory Board


We are presently forming The WIHS National Community Advisory Board (NCAB) which will represent the participants in the Women's Interagency HIV Study (WIHS). The Mission Statement of the NCAB is to:

  • Provide on-going community, science, psycho-social and political input to the national WIHS agenda.
  • Help design mechanism to assure that 100% of WIHS participants are representative for the community at large and to inform, educate and support these participants over time.
  • Help design mechanisms to assure access of HIV infected/affected women to WIHS research sites and retention of these participants over time.
  • Advocate for adequate research funding, to allow the full WIHS research agenda to be fulfilled.
  • Provide support for the site and/or local community advisory boards and encourage involvement at the local level.
  • Facilitate translation of WIHS related information to the community.Represent and be accessible to community members for WIHS related concerns.

The women of WIHS will be asked to maintain an ongoing representation of the thoughts and cares of the women who are affected by HIV and those who are at risk. The WIHS NCAB will be asked to meet regularly to discuss topics, discuss matters and have a little fun fellowship. Also a voted upon individual and an alternate will be asked to participant in representing our sites during national WIHS functions. As we go forward to advancing the HIV research field, we must ensure that the women of WIHS are properly hear and represented. We are asking if anyone is interested in being part of WIHS/NCAB please contact Zenoria Causey at



In between appoinments, Please check out our recent newsletters.

         Fall, Volume 1, Issue 1                             Spring 2016, Volume 1, Issue 2
Fall Volume 1 Issue 1               Spring 2016 Volume 1 issue 2